Rosenberg’s group had previously described that isolated tumor-reactive TILs from MM patients expressed PD-1 (61, 84), so they analyzed whether a permanent inhibition of PD-1 in engineered-TILs through zinc finger endonucleases (ZFN) gene-editing technique could improve the effectiveness of TIL after infusion. This evidence concerns the gene PDCD1 and Miyoshi myopathy.